Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver

• ClinicalTrials.gov Identifier: NCT00149396
• Recruitment Status: Completed
• First Posted: September 8, 2005
• Results First Posted: April 24, 2018
• Last Update Posted: April 24, 2018
• Sponsor: MediGene
• Information provided by (Responsible Party): MediGene

Study Description

Brief Summary:

This study is an open-label study. It has two stages. Stage 1 is a dose escalation phase of the study to determine and evaluate the safety and tolerability of repeated treatments with a genetically engineered herpes simplex virus NV1020 administered locoregionally to the liver.

Stage 2 is to evaluate the dose found in Stage 1 to be "optimally tolerated". Stage 2 is to assess the efficacy of the optimally tolerated dose of NV1020 by itself and in combination with second-line chemotherapy.

Assignment to Stage 1 or Stage 2 of the study is determined by when the patient enters the study.

Condition or disease	Intervention/treatment	Phase
Colorectal Cancer; Liver Neoplasms	Drug: NV1020	Phase 1; Phase 2

Detailed Description:

This study is designed to evaluate the effects of repeated treatments with NV1020, prior to second-line chemotherapy, and to determine an appropriate dose level of NV1020 in a multiple dose regimen for later Phase II studies.

Sequential, open-label cohort dose escalation of NV1020 (stage 1) followed by an expansion of one selected dose cohort (stage 2).

Study results will be reviewed periodically by an independent DSMB who will approve each cohort dose escalation.

During the dose escalation stage, 3 cohorts of patients (3 in each) will be treated with 4 fixed doses of NV1020, with the dose level increasing for successive cohorts. A patient will be observed for a minimum of 7 days after the first NV1020 infusion before the next patient in the same cohort is given NV1020. The first patient in the next higher dose cohort will receive NV1020 no earlier than 14 days after the last patient in the prior cohort has finished NV1020 infusions. One additional cohort (half log higher increment) may be approved by the DSMB, if considered necessary to define MTD. Dose-limiting toxicity will be determined using NCI CTC criteria and a suitable dose level for later evaluation will be selected.

In the second stage of the study, the dose cohort considered to show the best therapeutic index will be expanded by the addition of 18 further patients. For all patients in this study, investigational treatment with NV1020 will be followed by a minimum of two cycles of second-line therapy using anti-neoplastic drugs approved by the FDA for colorectal cancer and selected by the investigator.

All patients will be followed up periodically until death. Permission for autopsy will be sought.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 32 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver
• Study Start Date: July 2004
• Actual Primary Completion Date: October 2008
• Actual Study Completion Date: December 2008

Arms and Interventions

Arm

Intervention/treatment

Experimental: Safety and antitumor effects of NV1020; Stage 1: Four escalating dose cohorts of NV1020 3x10^6 pfu, 1x10^7 pfu, 3x10^7 pfu, and 1x10^8 pfu administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks followed by 2 cycles of chemotherapy. Stage 2: Expansion of one dose cohort from Stage 1 of optimal NV1020 dose administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks followed by 2 cycles of chemotherapy.

Drug: NV1020; NV1020 dose levels: 3x10^6, 1x10^7, 3x10^7, and 1x10^8 plaque forming units, administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks

Outcome Measures

Primary Outcome Measures :

1. Incidence of Adverse Events and Dose Limiting Adverse Events [ Time Frame: From start of treatment through 12 months after completion of treatment ]
   Incidence of adverse events for all patients (N=32); Overall incidence ≥20%; Adverse events listed by Medical Dictionary for Regulatory Activities (MedDRA) Preferred Term
2. NV1020 Pharmacokinetics - Presence of NV1020 in Body Fluids/Skin [ Time Frame: Daily for 2 weeks after the first and last NV1020 infusions ]
   Number of patients with NV1020 detected in saliva, skin, and/or mucosal surfaces; Analysis by polymerase chain reaction (PCR)
3. Clinical Laboratory Safety - Hematology [ Time Frame: Screening; after each NV1020 infusion; +7h, +24h, and +72h after NV1020 infusion; each chemotherapy visit; +3d, +7d, +14d after each chemo visit; 1 week after end of treatment ]
   Number of patients with clinically significant hematology laboratory abnormalities by NV1020 dose cohort (Post baseline)
4. Clinical Laboratory Safety - Chemistry [ Time Frame: Screening; after each NV1020 infusion; +7h, +24h, and +72h after NV1020 infusion; each chemotherapy visit; +3d, +7d, +14d after each chemo visit; 1 week after end of treatment ]
   Number of patients with post-baseline clinically significant laboratory chemistry abnormalities by NV1020 dose cohort
5. Clinical Laboratory Safety - Coagulation [ Time Frame: Screening; after each NV1020 infusion; +7h, +24h, and +72h after NV1020 infusion; each chemotherapy visit; +3d, +7d, +14d after each chemo visit; 1 week after end of treatment ]
   Number of patients with post-baseline clinically significant laboratory coagulation abnormalities by NV1020 dose cohort

Secondary Outcome Measures :

1. Mean Change From Baseline in Serum Carcinoembryonic Antigen (CEA) After Administration of NV1020 and 2 Cycles of Chemotherapy [ Time Frame: Screening (baseline), Chemo visit 1, Chemo visit 2, Follow-up Visit 1 (1 week after end of treatment), Follow-up Visit 2 (+6M), Follow-up Visit 3 (+9M), Follow-up Visit 4 (+12M) ]
2. Liver Tumor Response After Administration of NV1020 Followed by Chemotherapy, Determined by Radiological (Computed Tomography [CT] Scan) Assessment [ Time Frame: Screening (baseline), Chemo visit 1, Follow-up visits 1 (1 week post end of treatment), 2 (+6M), 3 (+9M), 4 (+12M) ]
   Maximum percentage changes in tumor diameter after administration of NV1020 followed by chemotherapy as measured by CT scan and Modified Response Evaluation Criteria in Solid Tumors (RECIST) assessment
3. Pharmacodynamic Effects of NV1020: NV1020 Neutralizing Antibody Titer Assay [ Time Frame: Screening, Chemo Visit 1, Follow-up Visits 1 (1 week post end of treatment), 2 (+6M), 3 (+9M), 4 (+12M) ]
   Mean change from baseline in NV1020 neutralizing antibody titer by dose cohort
4. Time to Disease Progression; Survival Time [ Time Frame: Progression: Chemo visit 1, FU1 (1 week post treatment), FU2 (+6M), FU3 (+9M), FU4 (+12M); Survival: death of patient ]
   Progression assessed from CT and PET measurements and is determined as an increase of greater than or equal to 25% in the sum of the products of perpendicular diameters of all tumors, or the appearance of any new lesion.
5. Pharmacodynamic Effects of NV1020: Serum Cytokines (INF Gamma) [ Time Frame: Baseline, after each NV1020 infusion (Visit 1, Visit 3, Visit 5, Visit 7) ]
   Median change from baseline of Interferon (INF) gamma 8 hours post NV1020 infusion (Visits 1, 3, 5, 7)
6. Pharmacodynamic Effects of NV1020: Serum Cytokines (IL-6) [ Time Frame: Baseline, after each NV1020 infusion (Visit 1, Visit 3, Visit 5, Visit 7) ]
   Median change from baseline of Interleukin-6 (IL-6) 8 hours post NV1020 infusion (Visits 1, 3, 5, 7)
7. Pharmacodynamic Effects of NV1020: Serum Cytokines (TNF-alpha) [ Time Frame: Baseline, after each NV1020 infusion (Visit 1, Visit 3, Visit 5, Visit 7) ]
   Median change from baseline of tumor necrosis factor (TNF-alpha) 8 hours post NV1020 infusion (Visits 1, 3, 5, 7)

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Ability to understand and willingness to sign a written informed consent (includes willingness to avoid physical intimacy during and for 2 weeks post NV1020 treatment)
2. 18 years or more of age
3. Colorectal adenocarcinoma histologically confirmed within one year prior to enrollment in the study
4. Liver dominant metastases (CT-measurable lesions with less than 50% total liver involvement), histologically confirmed
5. Failed conventional chemotherapy for metastatic disease (e.g. tumors no longer responding to 5-FU/leucovorin in combination with irinotecan or oxaliplatin with or without one monoclonal antibody)
6. Candidate for additional chemotherapy (and/or experimental anti-cancer therapy, if this is the only remaining treatment option)
7. Karnofsky Performance Status 70% or greater
8. Life expectancy greater than or equal to 4 months, based on the investigator's opinion
9. Seropositive for herpes simplex virus-1 (HSV-1)
10. Fecund females: negative for pregnancy test (urine or serum)
11. Effective double-barrier contraception for a minimum of 2 months following final infusion of NV1020

Exclusion Criteria:

1. Dominant extrahepatic disease, including cerebral metastases, significant malignant ascites or other extrahepatic metastases that are symptomatic, in critical locations or otherwise likely to confound NV1020 evaluations, in the opinion of the investigator
2. Seronegative for HSV-1

3. Significant active/unstable non-malignant disease or laboratory test (hematology and chemistry) results that meet any of the following:

   • White blood cell count (WBC) less than or equal to 3 x 10e3/mm3
   • Absolute neutrophil count (ANC) less than or equal to 1.5 x 10e3/mm3
   • Platelets less than or equal to 100,000/mm3
   • Hemoglobin (Hgb) less than or equal to 9.0 g/dL
   • Prothrombin time/partial thromboplastin time (PT/PTT) > upper limit of normal (ULN)
   • Serum creatinine > 2.0 mg/dL
   • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 times ULN or total bilirubin > 1.5 times ULN
   • Alkaline phosphatase > 2.5 times ULN
4. Chemotherapy < 4 weeks prior to the first NV1020 infusion (mitomycin or nitrosurea < 6 weeks)
5. Immunotherapy < 6 weeks prior to the first NV1020 infusion
6. Radiotherapy (external or internal) to the liver
7. Major surgery (excluding pump placement and cholecystectomy) ≤ 2 weeks prior to the first NV1020 infusion but the subject must be clinically stable. Pump placement and cholecystectomy ≤ 1 week prior to the first NV1020 infusion but the subject must be clinically stable
8. Female who is pregnant or nursing
9. Patients wishing to conceive within 2 months after the last infusion of NV1020
10. Any investigational agent administered less than or equal to 4 weeks prior to NV1020 infusion
11. Acute HSV infection requiring systemic antiviral therapy or history of serious HSV infection (e.g., ocular, encephalitic, etc.)
12. Active viral hepatitis (evidence for infection with hepatitis A, B or C viruses)
13. Known infection with HIV
14. Known hypersensitivity to any component of the NV1020 formulation
15. History of, or current, bleeding or coagulation disorder
16. History of significant hepatic fibrosis, cirrhosis, or hemachromatosis
17. History of malignancy other than colorectal cancer, within 5 years prior to start of study participation, with the exception of in situ cervical or skin carcinoma
18. Active severe infection and any other concurrent disease or medical conditions that are likely to interfere with the study, as judged by the investigator
19. Systemic corticosteroid administration < 4 weeks prior to starting NV1020 treatment
20. Prior treatment with NV1020 or other putative oncolytic viruses

Contacts and Locations

Locations

United States, California

University of California, San Diego

San Diego, California, United States, 92093

United States, Massachusetts

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

United States, Pennsylvania

University of Pittsburgh Cancer Center

Pittsburgh, Pennsylvania, United States, 15213

United States, Tennessee

University of Vanderbilt

Nashville, Tennessee, United States, 37232

United States, Texas

Mary Crowley Medical Research Center

Dallas, Texas, United States, 75201

Sponsors and Collaborators

MediGene

Investigators

• Study Director: Hoda Tawfik, PhD; MediGene

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Sze DY, Iagaru AH, Gambhir SS, De Haan HA, Reid TR. Response to intra-arterial oncolytic virotherapy with the herpes virus NV1020 evaluated by [18F]fluorodeoxyglucose positron emission tomography and computed tomography. Hum Gene Ther. 2012 Jan;23(1):91-7. doi: 10.1089/hum.2011.141. Epub 2011 Oct 14.

• Responsible Party: MediGene
• ClinicalTrials.gov Identifier: NCT00149396
• Other Study ID Numbers: CT1030
• First Posted: September 8, 2005
• Results First Posted: April 24, 2018
• Last Update Posted: April 24, 2018
• Last Verified: March 2018

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Keywords provided by MediGene:

Colorectal cancer metastases to liver; Colorectal Cancer; Colorectal Carcinoma; Colorectal Tumors; Colorectal Neoplasms; Rectum Cancer; Rectum tumors; Rectum carcinoma; Colon cancer; Colon tumors; Colon carcinoma; Rectum Neoplasms; Colon Neoplasms; Liver Neoplasms; Hepatic Neoplasms; Liver Tumors; Liver cancer; Hepatic Cancer; Hepatic tumors; metastatic to the liver

Additional relevant MeSH terms:

Neoplasms; Colorectal Neoplasms; Liver Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases; Liver Diseases